ASIA unversity:Item 310904400/4629
English  |  正體中文  |  简体中文  |  全文笔数/总笔数 : 93288/109022 (86%)
造访人次 : 20965325      在线人数 : 198
RC Version 6.0 © Powered By DSPACE, MIT. Enhanced by NTU Library IR team.
搜寻范围 查询小技巧:
  • 您可在西文检索词汇前后加上"双引号",以获取较精准的检索结果
  • 若欲以作者姓名搜寻,建议至进阶搜寻限定作者字段,可获得较完整数据
  • 进阶搜寻


    题名: P27kip1 down-regulation is associated with trastuzumab resistance in breast cancer cells
    作者: Nahta, R.;Takahahshi, T.;Ueno, N. T.;Mien-Chie Hung;Esteva, F. J.
    日期: 2004-06
    上传时间: 2009-11-27 13:57:08 (UTC+8)
    出版者: Asia University
    摘要: Trastuzumab (Herceptin) is a recombinant humanized monoclonal antibody directed against HER-2. The objective response rate to trastuzumab monotherapy is 12?34% for a median duration of 9 months, by which point most patients become resistant to treatment. We created two trastuzumab-resistant (TR) pools from the SKBR3 HER-2-overexpressing breast cancer cell line to study the mechanisms by which breast cancer cells escape trastuzumab-mediated growth inhibition. Both pools maintained her-2 gene amplification and protein overexpression. Resistant cells demonstrated a higher S-phase fraction by flow cytometry and a faster doubling time of 24?36 h compared with 72 h for parental cells. The cyclin-dependent kinase inhibitor p27kip1 was decreased in TR cells, and cyclin-dependent kinase 2 activity was increased. Importantly, exogenous addition of p27kip1 increased trastuzumab sensitivity. Additionally, resistant cells displayed heightened sensitivity to the proteasome inhibitor MG132, which induced p27kip1 expression. Thus, we propose that trastuzumab resistance may be associated with decreased p27kip1 levels and may be susceptible to treatments that induce p27kip1 expression.
    關聯: CANCER RESEARCH 64(-):3981-3986
    显示于类别:[生物科技學系] 期刊論文


    档案 描述 大小格式浏览次数
    310904400-4629.doc34KbMicrosoft Word455检视/开启


    DSpace Software Copyright © 2002-2004  MIT &  Hewlett-Packard  /   Enhanced by   NTU Library IR team Copyright ©   - 回馈